Skip to content

Observation on the therapeutic effect of TaVNS combined with rTMS on upper limb motor dysfunction after stroke

Observation on the therapeutic effect of TaVNS combined with rTMS on upper limb motor dysfunction after stroke

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102634
Enrollment
Unknown
Registered
2025-05-16
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

Combined intervention group:rTMS,taVNS
rTMS group:rTMS, Sham taVNS
taVNS group:taVNS, Sham rTMS
Control group:Sham rTMS and taVNS

Sponsors

The Second Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Right-handed patients with first-onset stroke who meet the diagnostic criteria for stroke; 2. Unilateral lesions confirmed by CT or MRI as hemorrhagic or ischemic lesions in the basal ganglia region; 3. Disease course of 15 days to 2 months, regardless of gender, aged 40 to 80 years;4.Clear consciousness and stable vital signs; 5.Upper limb dysfunction, Brunnstrom stage II to IV and upper limb Fugl-Meyer score <43 points;6.No mental abnormalities; 7.Agree to the rehabilitation program and be able to cooperate with treatment guidance;8.Patients and/or family members understand and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with severe cognitive impairment or mental illness who cannot cooperate with treatment and evaluation; 2.Metal foreign bodies in the brain;3.History of epilepsy or family history of epilepsy;4. Patients with pacemakers, stents, or cochlear implants; 5.Heart rate less than 60 beats/min; 6.Patients with infection, ulcers, or scars on the auricle; 7. Severe spasms, i.e., modified Ashworth grade exceeding grade III; 8.Patients who cannot tolerate treatment or cannot cooperate with the follow-up of the trial progress.

Design outcomes

Primary

MeasureTime frame
FMA-LE scale score;Functional near-infrared spectroscopy imaging technology: brain functional connectivity;

Secondary

MeasureTime frame
MBI scale score;Modified Ashworth Scale scale score;Brunnstrom scale score;Hospital Anxiety and Depression Scale score;

Countries

China

Contacts

Public ContactLitong Wang

The Second Affiliated Hospital of Dalian Medical University

litongwanglv@163.com+86 177 0987 6587

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026